FMT holds potential for treating various diseases beyond C. difficile infection, but its regulation by the FDA is crucial due to concerns about long-term effects and unintentional disease transfer.
Keep Reading
Add A Comment
Trending
- 5 doctors weigh in on the promise, limitations of Grail’s multicancer test (Medtech Dive)
- IBS Pain Closely Linked to Interrelated Daily-Life Triggers (Physicians Weekly)
- First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication (Takeda)
- Industry Voices—How physician practices can grow and succeed without the support of private equity (Fierce Healthcare)
- Blood-Based CRC Test Upgrades Improve on Precancerous Lesion Detection (Medscape)
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing (Lucid Diagnostics)
- How Can GI Fellowship Programs Enhance Ambulatory Training? (Yale School of Medicine)
- VIOVOC Issued U.S. Patent for Ambient Sensing Technology That Decodes Gut Microbiome Signals (Business Wire)
